Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-DOTA-TATE + olaparib
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
177Lu-DOTA-TATE + olaparib is an investigational combination therapy consisting of a radiopharmaceutical, 177Lu-DOTA-TATE (Lutathera), and a small molecule PARP inhibitor, olaparib (Lynparza). 177Lu-DOTA-TATE is a peptide receptor radionuclide therapy (PRRT) that targets somatostatin receptors on neuroendocrine tumor cells, delivering targeted radiation to induce DNA damage. Olaparib inhibits poly(ADP-ribose) polymerase (PARP), impairing the repair of single-strand DNA breaks. The rationale for combining these agents is to potentiate the cytotoxic effects of PRRT by preventing tumor cells from repairing radiation-induced DNA damage, thereby increasing cell death. This combination is being studied primarily in patients with somatostatin receptor-positive neuroendocrine tumors[1][2][3][4][6].
- Brand names
- Lutathera + Lynparza
- Other names
- Lutetium Lu 177 dotatateDOTA0-Tyr3-OctreotateDOTA-0-Tyr3-OctreotateDOTA 0-Tyr3-OctreotateAZD2281AZD-2281AZD 2281
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)Pol II (RNA polymerase II elongation factors)SSTR2 (Somatostatin receptor type 2)SSTR5 (Somatostatin receptor 5)SSTR (Somatostatin receptors)
Beyond the preview
Go deeper on 177Lu-DOTA-TATE + olaparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-DOTA-TATE + olaparib.